Treatment.Com International Inc. (TRUE.CN)
CAD 0.41
(-1.22%)
CAD 0.41
(-1.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.64 Million CAD | 38.56% |
| 2022 | - CAD | 72.79% |
| 2021 | - CAD | -378.63% |
| 2020 | -2.9 Million CAD | -275.27% |
| 2019 | - CAD | 2467.71% |
| 2018 | - CAD | 27.39% |
| 2017 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.72 Million CAD | -198.65% |
| 2024 Q1 | -904.03 Thousand CAD | 58.8% |
| 2023 Q2 | -269.12 Thousand CAD | 25.78% |
| 2023 Q4 | -851.64 Thousand CAD | -0.96% |
| 2023 Q3 | -843.56 Thousand CAD | -213.44% |
| 2023 FY | - CAD | 38.56% |
| 2023 Q1 | -362.6 Thousand CAD | 56.64% |
| 2022 Q4 | -836.23 Thousand CAD | -139.61% |
| 2022 Q3 | -349 Thousand CAD | 40.61% |
| 2022 Q2 | -587.62 Thousand CAD | 71.7% |
| 2022 FY | - CAD | 72.79% |
| 2022 Q1 | -2.07 Million CAD | 65.0% |
| 2021 Q4 | -5.93 Million CAD | -27.42% |
| 2021 FY | - CAD | -378.63% |
| 2021 Q3 | -4.65 Million CAD | -106.64% |
| 2021 Q2 | -2.25 Million CAD | -109.4% |
| 2021 Q1 | -1.07 Million CAD | 15.62% |
| 2020 Q4 | -1.27 Million CAD | -101.1% |
| 2020 FY | - CAD | -275.27% |
| 2020 Q3 | -634.21 Thousand CAD | 15.73% |
| 2020 Q2 | -752.61 Thousand CAD | -205.88% |
| 2020 Q1 | -246.04 Thousand CAD | 89.04% |
| 2019 Q4 | -2.24 Million CAD | -135872.08% |
| 2019 FY | - CAD | 2467.71% |
| 2019 Q3 | -1651.00 CAD | 0.0% |
| 2018 FY | - CAD | 27.39% |
| 2017 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AI/ML Innovations Inc. | -1.66 Million CAD | -119.021% |
| Diagnamed Holdings Corp. | -100.27 Thousand CAD | -3536.597% |
| Pangenomic Health Inc. | -2.71 Million CAD | -34.467% |
| nDatalyze Corp. | -290.5 Thousand CAD | -1155.229% |
| Unidoc Health Corp. | -2.18 Million CAD | -67.046% |